Page 633«..1020..632633634635..640650..»

Stem Cell Therapy (IMC) – Video

By JoanneRUSSELL25


Stem Cell Therapy (IMC)
New Project 40From:OmarGonzalezMDViews:0 0ratingsTime:01:48More inScience Technology

Read more here:
Stem Cell Therapy (IMC) - Video

To Read More: Stem Cell Therapy (IMC) – Video
categoriaUncategorized commentoComments Off on Stem Cell Therapy (IMC) – Video | dataDecember 10th, 2012
Read All

Sources Of Stem Cells | Stem Cell Malaysia – Video

By raymumme


Sources Of Stem Cells | Stem Cell Malaysia
stemcellmalaysia.com Sources of stem cells play a critical role in determining the outcome of stem cell therapy. Without a clear idea of the sources of stem cells, it is risky to be engaged in any form of stem cells treatment. The sources of stem cells include the type of animals, the location of the animals, and the parts of the animal. For more information on sources of stem cells, please visit Stem Cell Malaysia at stemcellmalaysia.comFrom:stemcells2012Views:207 9ratingsTime:04:13More inScience Technology

Read more:
Sources Of Stem Cells | Stem Cell Malaysia - Video

To Read More: Sources Of Stem Cells | Stem Cell Malaysia – Video
categoriaUncategorized commentoComments Off on Sources Of Stem Cells | Stem Cell Malaysia – Video | dataDecember 10th, 2012
Read All

Robert Toves Testimonial (Parkinson’s Disease) Stem Cell Therapy – Video

By daniellenierenberg


Robert Toves Testimonial (Parkinson #39;s Disease) Stem Cell Therapy
Robert Toves is a patient at Integra Medical Center, Mr.Toves suffers of Parkinson #39;s disease and has come to try Dr.Gonzalez method of stem cell therapy, just less than an hour after the stem cell therapy great results seem to show.From:OmarGonzalezMDViews:1 0ratingsTime:05:58More inScience Technology

Read more here:
Robert Toves Testimonial (Parkinson's Disease) Stem Cell Therapy - Video

To Read More: Robert Toves Testimonial (Parkinson’s Disease) Stem Cell Therapy – Video
categoriaUncategorized commentoComments Off on Robert Toves Testimonial (Parkinson’s Disease) Stem Cell Therapy – Video | dataDecember 10th, 2012
Read All

Stem Cell Therapy (Cerebral Palsy) – Video

By Dr. Matthew Watson


Stem Cell Therapy (Cerebral Palsy)
New Project 43From:OmarGonzalezMDViews:3 0ratingsTime:02:07More inScience Technology

Read more here:
Stem Cell Therapy (Cerebral Palsy) - Video

To Read More: Stem Cell Therapy (Cerebral Palsy) – Video
categoriaUncategorized commentoComments Off on Stem Cell Therapy (Cerebral Palsy) – Video | dataDecember 10th, 2012
Read All

Stem Cell Therapy – Let Your Own Stem Cells Make Wrinkles Virtually Disappear! Free postage – Video

By daniellenierenberg


Stem Cell Therapy - Let Your Own Stem Cells Make Wrinkles Virtually Disappear! Free postage
Stem Cell Therapy - Let Your Own Stem Cells Make Wrinkles Virtually Disappear!From:Deals2uTVViews:0 0ratingsTime:02:01More inHowto Style

See the rest here:
Stem Cell Therapy - Let Your Own Stem Cells Make Wrinkles Virtually Disappear! Free postage - Video

To Read More: Stem Cell Therapy – Let Your Own Stem Cells Make Wrinkles Virtually Disappear! Free postage – Video
categoriaUncategorized commentoComments Off on Stem Cell Therapy – Let Your Own Stem Cells Make Wrinkles Virtually Disappear! Free postage – Video | dataDecember 10th, 2012
Read All

Top trends for Biotechnology

By Dr. Matthew Watson

Biotechnology simply means to develop or to make useful products with the help of using living systems. Over the years mankind has used biotechnology in several sectors like agriculture, food production and medicine. There are several sectors in which biotechnology can affect severely.

Biotech for human enhancement is the most profitable industry in the 21st century. Careers are influenced by genetic heritage. It is said that by 2020 people will be able to decipher human genome

Which is nothing but the blueprint of our DNA? One of the trends is towards the genetic solutions to the ills. There are several newly discovered drugs will save countless no of lives. These drugs can also eliminate many diseases. A lot of research works have been done on the recent trends for biotechnology. Research output continues to shift to ASIA. The current trends in biotechnology are its association with pharmacy. It is said that within few more years people will be able to turn on or turn off certain genes which can influence on health and performance. People can eliminate unwanted characteristics by using altered genes from their babies. People can also enhance their babies’ capabilities by using the same method. There is different classification of biotechnology having different application of each. Like white or industrial biotechnology helps in the production of chemical base materials and end products. Red biotechnology means development of new medical drugs. Biotechnology is the driving factor behind many applications in medicine. Green or Plant biotechnology is used in production of plants which are renewable recourses. Biotechnology is integrated use of many biological technologies. It also has trends in horticulture. One of the emerging trends in Biotechnology have been observed and noted in recent years. One such trend is the trend in partnering and acquisition of deals. This is applicable to the business perspective towards the delivery and realization of more up to date by products. So basically there are a lot of sectors in which biotechnology can affect. But one of the most suitable choices is pharmaceutical sector. People are focusing more and more now days on the use of biotechnological products. There are a lot of independent biotechnology companies which deals directly with these biotechnological products. Biotechnology is used to develop commercial product also. Biotechnology becomes central priority of the government’s research policy to ensure a high standing of biosciences and to develop newer innovation techniques. At present there are 25 different initiatives to financially support universities, research institutes. They all are working like a chain having same common objectives. There is a healthy competition in between the companies which in turn increases the level of biotechnological products. The key element of this initiative is Biopharma competition. So it depends on the people how they utilize biotechnological products for their better interest.

Biotechnology is a technology which never goes opposite to the nature.

We have to improve the biotechnology with the help of nature. Now a days lots of course are based on Biotechnology in various colleges all over the world. It becomes popular to all the students also.

Source:
http://www.biotechblog.org/entry/top-trends-biotechnology/

To Read More: Top trends for Biotechnology
categoriaUncategorized commentoComments Off on Top trends for Biotechnology | dataDecember 9th, 2012
Read All

Billionaires push for Geneva research centre – swissinfo.ch

By Dr. Matthew Watson


swissinfo.ch
Billionaires push for Geneva research centre
swissinfo.ch
At a press conference in Bern on Wednesday, the consortium, which includes the Federal Institute of Technology in Lausanne (EPFL) and Geneva University, said the centre would focus on research in the areas of health, biotechnology and life sciences.

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNFWCC10_wOgk-P06uWd9W7IEw90lg&url=http://www.swissinfo.ch/eng/science_technology/Billionaires_push_for_Geneva_research_centre.html?cid%3D34116782

To Read More: Billionaires push for Geneva research centre – swissinfo.ch
categoriaUncategorized commentoComments Off on Billionaires push for Geneva research centre – swissinfo.ch | dataDecember 9th, 2012
Read All

NASA funds astrobiology research by Delaware Biotechnology Institute scientist – University of Delaware

By Dr. Matthew Watson


University of Delaware
NASA funds astrobiology research by Delaware Biotechnology Institute scientist
University of Delaware
9:02 a.m., Dec. 3, 2012--Does life exist anywhere else in the universe? That's the type of broad but poignant question NASA likes to ask, according to Chandran Sabanayagam, associate scientist in the Bioimaging Center at the Delaware Biotechnology ...

and more »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNFERLNhu91w5KszujZY2zU2jjwDRA&url=http://www.udel.edu/udaily/2013/dec/dbi-nasa-astrobiology-120312.html

To Read More: NASA funds astrobiology research by Delaware Biotechnology Institute scientist – University of Delaware
categoriaUncategorized commentoComments Off on NASA funds astrobiology research by Delaware Biotechnology Institute scientist – University of Delaware | dataDecember 9th, 2012
Read All

UAB researcher named AAAS Fellow – UAB News

By Dr. Matthew Watson


UAB News
UAB researcher named AAAS Fellow
UAB News
N. Rama Krishna, Ph.D., professor in the UAB Department of Biochemistry and Molecular Genetics, has been named as a fellow of the American Association for the Advancement of Science (AAAS) by his peers in the organization. Krishna also is the director ...
UMass Medical School faculty elected to the American Association for the ...Phys.Org (press release)

all 45 news articles »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNGX4pMkXktXEGFZDvFV_SwSKFe_MQ&url=http://www.uab.edu/news/briefs/item/2956-uab-researcher-named-aaas-fellow

To Read More: UAB researcher named AAAS Fellow – UAB News
categoriaUncategorized commentoComments Off on UAB researcher named AAAS Fellow – UAB News | dataDecember 9th, 2012
Read All

Chicago Bears hit the jackpot with WR Brandon Marshall – SB Nation

By Dr. Matthew Watson


SB Nation
Chicago Bears hit the jackpot with WR Brandon Marshall
SB Nation
You don't need to sort through reams of data or major in molecular genetics to have a working knowledge of just how pathetic Chicago Bears quarterbacks have been since, oh, the dawn of time. The franchise's most revered and accomplished passer to date ...

and more »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNH5PXI0N9CVy3Osj2fI26xIU6OsQA&url=http://chicago.sbnation.com/chicago-bears/2012/12/7/3740098/chicago-bears-brandon-marshall-jay-cutler-stats

To Read More: Chicago Bears hit the jackpot with WR Brandon Marshall – SB Nation
categoriaUncategorized commentoComments Off on Chicago Bears hit the jackpot with WR Brandon Marshall – SB Nation | dataDecember 9th, 2012
Read All

Frustration over lack of valley fever drugs – Merced Sun-Star

By Dr. Matthew Watson


Merced Sun-Star
Frustration over lack of valley fever drugs
Merced Sun-Star
It's "a clear, unmet clinical need," said Dr. Joseph Heitman, chairman of Duke University's Department of Molecular Genetics and Microbiology. Even when treatments do fight off valley fever, they can cause significant side effects. Pregnant women can't ...

and more »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNF9jVy2ZY3TwrPblfzNwEe4QPLGkQ&url=http://www.mercedsunstar.com/2012/12/08/2694456/frustration-over-lack-of-valley.html

To Read More: Frustration over lack of valley fever drugs – Merced Sun-Star
categoriaUncategorized commentoComments Off on Frustration over lack of valley fever drugs – Merced Sun-Star | dataDecember 9th, 2012
Read All

2002 Buckeyes: Director Krenzel – Toledo Blade

By Dr. Matthew Watson


Toledo Blade
2002 Buckeyes: Director Krenzel
Toledo Blade
At OSU, the quarterback conducted cancer research, balanced the title run with a graduate-level course load of Molecular Genetics 608, Molecular Genetics 701, and Microbiology, and graduated with a 3.75 GPA. If the fall of 2002 taught him anything, it ...

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNFPF38Y3m3n1SYafkKGa2wn-Yp5VA&url=http://www.toledoblade.com/Ohio-State/2012/11/11/Ohio-State-QB-Krenzel-It-was-meant-to-be.html

To Read More: 2002 Buckeyes: Director Krenzel – Toledo Blade
categoriaUncategorized commentoComments Off on 2002 Buckeyes: Director Krenzel – Toledo Blade | dataDecember 9th, 2012
Read All

Brooklyn science club mixes beer with research talk – Newsday

By Dr. Matthew Watson


Newsday
Brooklyn science club mixes beer with research talk
Newsday
The molecular genetics. The marine biology. The neuroscience. Those are the topics of the Secret Science Club, a monthly event that brings people to hear scientists and researchers talking about their work, accompanied by signature cocktails like the ...
Secret science club mixes knowledge with cocktailsPallTimes.com

all 25 news articles »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHavX3RCZu2VX065xGAK7a1kZdpeA&url=http://www.newsday.com/news/new-york/brooklyn-science-club-mixes-beer-with-research-talk-1.4256956

To Read More: Brooklyn science club mixes beer with research talk – Newsday
categoriaUncategorized commentoComments Off on Brooklyn science club mixes beer with research talk – Newsday | dataDecember 9th, 2012
Read All

Stem Cell Agency Chairman Says IOM Report ‘Quite Complimentary’

By Dr. Matthew Watson

Jonathan Thomas
CIRM Photo

Jonathan Thomas, the Los Angeles bond
financier who is chairman of the $3 billion California stem cell agency, has
weighed in at more length on the sweeping recommendations from the
Institute of Medicine for changes at the agency.

He wrote a piece for the agency's blog
that said the 124-page report was “quite complimentary.” Thomas' article carried forward the theme of the stem cell agency's press
release yesterday that said the IOM “praises the agency as a 'bold
social innovation.'”
Thomas did acknowledge that the report
“highlighted some areas and made some recommendations about where
and how we might improve our performance.” 
Thomas concluded by saying the agency
takes the report seriously and will, over the next few months,
consider how best to respond.
Nearly needless to say, other observers
of the agency differ with Thomas' characterization of the report as
“quite complimentary.(See here and here.)

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/HmbrFtBzcs4/stem-cell-agency-chairman-says-iom.html

To Read More: Stem Cell Agency Chairman Says IOM Report ‘Quite Complimentary’
categoriaStem Cell Therapy commentoComments Off on Stem Cell Agency Chairman Says IOM Report ‘Quite Complimentary’ | dataDecember 9th, 2012
Read All

IOM Proposals for Overhaul at CIRM Win High Marks

By Dr. Matthew Watson

The Institute of Medicine's
recommendations for major changes at the California stem cell agency
today received generally high marks from independent observers and
critics.

Many of the proposals echoed
suggestions from California's Little Hoover Commission, the
state's good government agency. Asked for comment, Stuart Drown, the
commission's executive director, said,

“The institute’s recommendations
for much-needed changes to CIRM’s governance structure to provide
greater efficiency, clarity and accountability reinforce the
recommendations the Little Hoover Commission made in 2009."

He continued,

“Then and now, the Commission’s
recommendations are aimed at improving CIRM’s ability to meet its
goals for the good of all who can benefit from stem cell research,
and to ensure that California taxpayers’ dollars are put to their
most efficient use to that end.”

The California Stem Cell Report also
asked the agency's first president, Zach Hall, for his thoughts. Here
is the full text of what Hall, who was one of the peer reviewers on
the IOM study, had to say,

“The IOM Committee and its staff have
done an impressive job.  The report recognizes the scientific
value and achievements of the CIRM and, at the same time, makes
cogent recommendations that, if taken seriously, will further improve
the quality and the public credibility of the Institute. The
committee and staff deserve the thanks of the scientific community
and all California citizens for their careful and thoughtful work.” 

John M. Simpson, stem cell project
director for Consumer Watchdog of Santa Monica, Ca., said,

“It's long past time to make the
changes the report calls for, but given the spin the agency put on
its response -- saying the report praises the 'agency as a bold
innovation' -- shows it's business as usual. This sort of behavior
will only ensure that CIRM doesn't get another round of public
funding,” 

Marcy Darnovsky, associate executive
director of the Center for Genetics and Society of Berkeley, Ca.,
welcomed the recommendations. But she said,

“Given the agency’s shortcomings
and the state’s budgetary problems, it would be wrong to ask
Californians to give it more public money. If the agency acquires new
funds from industry sources or venture firms, it must recognize that
it has ongoing obligations to the people of California.” 

She continued,

 “CIRM has not
responded in a meaningful way to many previous public interest
suggestions or to independent reviews, including the one in 2009 by
the state’s Little Hoover Commission. We hope the agency will not
continue that pattern.” 

The California Stem Cell Report also
queried most of the 10 patient advocates on the agency's governing
board for comment. Their roles could be altered in a major way by the
IOM recommendations. None of the advocates have yet responded.
(The full text or nearly
full text of all the above comments is available here.)  

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/yyZ0TAisMZQ/iom-proposals-for-overhaul-at-cirm-win.html

To Read More: IOM Proposals for Overhaul at CIRM Win High Marks
categoriaStem Cell Therapy commentoComments Off on IOM Proposals for Overhaul at CIRM Win High Marks | dataDecember 9th, 2012
Read All

Text of Comments Reacting to IOM Report on California Stem Cell Agency

By Dr. Matthew Watson

Here is the full text or the essential
elements of comments sought by the California Stem Cell Report on the
Institute of Medicine report that recommended sweeping changes at the
California stem cell agency. Consumer Watchdog and the Center for
Genetics and Society
put their comments in the form of news releases,
which contained redundant material.

From Stuart Drown, executive director
of California's Little Hoover Commission:

“CIRM initiated the Institute of
Medicine review, which is to its credit.  The Institute of
Medicine took a scrupulous and rigorous approach to its review of the
California Institute of Regenerative Medicine and in its report,
notes CIRM’s many achievements and accomplishments.

“The Institute’s recommendations
for much-needed changes to CIRM’s governance structure to provide
greater efficiency, clarity and accountability reinforce the
recommendations the Little Hoover Commission made in 2009. The
institute graciously acknowledged the commission’s work, which
clearly is as relevant now as it was in 2009.

“Then and now, the Commission’s
recommendations are aimed at improving CIRM’s ability to meet its
goals for the good of all who can benefit from stem cell research,
and to ensure that California taxpayers’ dollars are put to their
most efficient use to that end.”

From John M. Simpson, stem cell project
director at Consumer Watchdog of Santa Monica, Ca.(full press release here):

“Consumer Watchdog Thursday welcomed
a report from the prestigious Institute of Medicine (IOM) calling for
sweeping reforms in governance at California’s stem cell agency and
an end to the board’s built-in conflicts of interest. 

“The report said that 'far too many
board members represent organizations' that receive funding or
benefit from the stem cell agency. The IOM said that the board’s
oversight function should be separated from the day-to-day management
of the California Institute for Regenerative Medicine (CIRM). 

“'The IOM's critical report echoes
what every independent evaluator has said in the past,' said John
M. Simpson, Consumer Watchdog’s Stem Cell Project director.
'As we have repeated from the beginning, CIRM suffers from built-in
conflicts of interest and needs to separate the board's oversight
function from day-to-day management.'

“'It's long past time to make the
changes the report calls for, but given the spin the agency put on
its response -- saying the report praises the 'agency as a bold
innovation' -- shows it's business as usual. This sort of behavior
will only ensure that CIRM doesn't get another round of public
funding,' Simpson said.”

From Marcy Darnovsky, associate
executive director of the Center for Genetics and Society in
Berkeley, Ca.(full press release here):

“The Center for Genetics and Society,
a nonprofit policy research and advocacy organization, welcomed the
report on the California stem cell agency released today by the
Institute of Medicine and called for stronger protections for  the interests of Californians as
the agency continues its disbursement of public funds.

“CIRM is nearing the end of the
billions of dollars of public funding allocated to it in
2004. The agency is currently considering how to extend
its operations after the money runs out. CGS Associate Executive
Director Marcy Darnovskysaid, “Given the agency’s
shortcomings and the state’s budgetary problems, it would be wrong
to ask Californians to give it more public money. If the agency
acquires new funds from industry sources or venture firms, it must
recognize that it has ongoing obligations to the people of
California.”

“She continued, 'CIRM has not
responded in a meaningful way to many previous public interest
suggestions or to independent reviews, including the one in 2008 by
the state’s Little Hoover Commission. We hope the agency will not
continue that pattern.' 

“'Today’s report from the IOM
reaffirms the significance of the conflicts of interest and
structural flaws that were built into the stem cell program from the
beginning, and that continue to threaten its credibility and
effectiveness. These are serious problems that the Center for
Genetics and Society and other public interest voices pointed out
even before the agency was approved by the 2004 ballot measure on
which backers spent some $35 million. 

“'Many aspects of these early
concerns remain directly relevant,' Darnovsky said. 'There is
still no way for elected officials to provide oversight because the
measure that created CIRM requires a 70% vote by both houses – more
than a supermajority. The agency’s governing board is still tainted
by its built-in conflicts of interest, and still includes no
representation of the public beyond disease advocates. Members of the
agency’s powerful Working Groups, including the one that reviews
grant applications, are still not required to publicly disclose their
individual financial interests.'”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/iu4DrhoewYo/text-of-comments-reacting-to-iom-report.html

To Read More: Text of Comments Reacting to IOM Report on California Stem Cell Agency
categoriaStem Cell Therapy commentoComments Off on Text of Comments Reacting to IOM Report on California Stem Cell Agency | dataDecember 9th, 2012
Read All

More IOM-CIRM Coverage: One Story Notes Major 2007 Conflict Flaps at Stem Cell Agency

By Dr. Matthew Watson

Additional coverage emerged this morning,
including stories in the Los Angeles Times, the Nature web site and
Businessweek. on a blue-ribbon report that recommended sweeping changes
at the the $3 billion California stem cell agency

In the Times, California's largest
circulation newspaper, Eryn Brown's story was headlined,

"Stem cell
agency board criticized for conflicts of interest."

The article began,

"The board of California's stem cell
funding agency is rife with conflicts of interest and should be
restructured to improve the integrity of its grant-making process,
according to a new report from independent experts convened by the
national Institute of Medicine."“

In the San Diego U-T, reporter Bradley
Fikes
' article was the only piece in all the coverage to mention two major conflict-of-interest flaps at the agency in 2007.
One involved then CIRM board member
John Reed, head of Sanford-Burnham in La Jolla, who tried to influence CIRM staff
in connection with a grant to his organization, triggering
an investigation by the state's political ethics commission. (Reed's
actions were first disclosed by the California Stem Cell Report.) The
other case involved inappropriate actions by four members of the
29-member board in an $85 million round. Ten applications were dumped
from the round because of the directors' actions. The conflict
issues were so rampant that only eight of the directors present at a
December 2007 meeting could discuss the issues.
(See here, here and here.)
On the Nature news blog, Monya Baker
had a thorough piece that said the agency “received a mixture of
praise and hard-to-enact recommendations from an august scientific
body.” She also wrote,

“It’s unclear what effect the
report will have. Many of these recommendations run counter to
requirements enshrined in the legislation that created CIRM, and the
board of CIRM has heard similar recommendations before and failed to
act on them.”

On the web site of the journal Science,
Greg Miller wrote that IOM report "praises the California Institute for
Regenerative Medicine
(CIRM) as a 'bold social innovation' that
provided a creative new source of funding that has turned the state
into an international hub of stem cell research. But the IOM panel
authoring the report also concluded that the funding agency’s
organization and governance is not optimal."
Businessweek carried the AP story by
Alicia Chang mentioned yesterday. The AP story also appeared on the San
Francisco Chronicle
and Sacramento Bee web sites and was also carried internationally on other web sites.  The Chronicle also had a staff story by Erin Allday.  
(An earlier version of this item did not contain the last sentence regarding the Allday story.)

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/yk8zuHF6IKA/more-iom-cirm-coverage-one-story-notes.html

To Read More: More IOM-CIRM Coverage: One Story Notes Major 2007 Conflict Flaps at Stem Cell Agency
categoriaStem Cell Therapy commentoComments Off on More IOM-CIRM Coverage: One Story Notes Major 2007 Conflict Flaps at Stem Cell Agency | dataDecember 9th, 2012
Read All

Coverage of the IOM Report: Light but a Column with a Cutting Edge

By Dr. Matthew Watson

News coverage has been light so far
today of the Institute of Medicine's recommendations for an overhaul
at the $3 billion California stem cell agency. But a Pulitzer Prize-winning columnist from the Los Angeles Times took a sharp knife to the agency's press release on the IOM report.

Michael Hiltzik, who is a regular critic of the agency, asked,

 "So how did CIRM react to the report? Even before the review panel's conference call with the press was completed, the agency issued a news release stating that the panel had 'praised' the agency 'for its ground breaking work in helping advance the science of stem cell research.'"If you wanted to know about the committee's criticisms, the first mention of those was in paragraph 9 of the news release. It quoted board Chairman Jonathan Thomas as promising to 'work on establishing a process to enable us to consider how best to proceed with reviewing the recommendations.' 

"By my count, that's seven steps it will take before actually acting on the recommendations. 

"As it happens, the panel's recommendations, which include creating a majority of independent board members without any potential conflicts of interest, track very closely to recommendations made by several previous outside reviews of CIRM, especially a 2009 study by the state's Little Hoover Commission.

"CIRM rejected almost every one, and it looks to be preparing to circle the wagons again against sensible improvements in the way it does business."

The Associated Press story by Alicia
Chang 
popped up in two different forms on the Washington
Post
web site and in Ottowa and Spokane, among other places. Chang
was on board for the IOM news conference and had this to say about
CIRM from one of the IOM study group members.

“'They’re not broken but they’re
bent,' said Sharon Terry, president of the nonprofit Genetic Alliance
who was part of the panel. 'They need some correction.'”

Chang's story originally began,

“California has transformed into a
powerhouse player in stem cell research, but the taxpayer-funded
institute responsible for that needs an overhaul, a report released
Thursday found.”

Another version, that appeared in
Ottowa and Spokane and beyond, started this way,
“A report says California’s stem
cell agency needs more independent oversight and recommends a
restructuring to avoid the appearance of conflict of interest.”
Ron Leuty of the San Francisco
Business, who is one of perhaps two reporters who regularly cover
the stem cell agency, wrote,

“A review of California's stem cell
research funding agency proposed changes to the agency's governing
structure and commercial goals while praising its results so far. The
124-page report from the Institute
of Medicine
 recycles many conflict of interest and
intellectual property concerns that have dogged the San
Francisco-based” agency.

Stephanie O'Neill at KPCC radio in Los
Angeles also had a story.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/XpN8S2N2-iw/coverage-of-iom-report-light-but-column.html

To Read More: Coverage of the IOM Report: Light but a Column with a Cutting Edge
categoriaStem Cell Therapy commentoComments Off on Coverage of the IOM Report: Light but a Column with a Cutting Edge | dataDecember 9th, 2012
Read All

IOM Recommends Sweeping Changes at California Stem Cell Agency

By Dr. Matthew Watson

A blue-ribbon study of the $3 billion
California stem cell agency today said the program has “achieved
many notable results,” but recommended sweeping changes to remove
conflict of interest problems, clean up a troubling dual-executive
arrangement and fundamentally change the nature of the governing
board.

The recommendations from the 17-month
study by the Institute of Medicine (IOM) would strip the board of its ability to approve individual
grants, greatly strengthen the role of the agency's president,
significantly alter the role of patient advocates on the governing
board and engage the biotech industry more vigorously.
Harold Shapiro, chairman of
IOM-CIRM  panel
Princeton University Photo

Harold Shapiro, former president of
Princeton University and chairman of the IOM study panel, said,
“Overall, CIRM (the California
Institute for Regenerative Medicine
) has done a remarkably good job”
in giving the state a prominent position in regenerative medicine.
But he said the stem cell field has “evolved”and CIRM needs to
change with it.
As for turning research into cures, the
report said,

 “The challenge of moving its research programs
closer to the clinic and California’s large biotechnology sector is
certainly on CIRM’s agenda, but substantial achievements in this
arena remain to be made.”

Asked for comment, J.T. Thomas, chairman of the CIRM governing board, said it was premature to offer an opinion on the report, which will be presented to directors Dec. 12 at their Los Angeles meeting. (See here for the full text of Thomas' remarks.)
The study was conducted at the behest
of CIRM, which paid the IOM $700,000. The IOM is a prestigious
non-profit organization that was created in 1970 to provide
authoritative advice to policy makers and the public.
In 2010, when directors authorized the
study, Robert Klein, then chairman of the CIRM board, and other board
members said that they hoped the study would lead to
another multibillion dollar state bond issue to support the
agency(see here and here). Duane Roth, a San Diego businessman and co-vice chairman of
the CIRM governing board, was the lone no vote on the study. He
warned directors that that they could not “go in just sort of blind
trust that (the IOM is) going to reach the conclusion you want them
to reach.”
The agency will run out cash for new
grants in four years. Currently California remains in the throes of
state budgetary problems, and the agency has put on hold talk of another bond
election. It has also broached the possibility of
seeking private funding.
The IOM report said the agency should
develop a full-blown “sustainability platform” and plans that would
spell out its likely financial structure and future rules on grants
and their administration, including intellectual property.
The study echoed concerns and
complaints about CIRM's operation that were aired even before the
agency was officially created by voters in 2004. One of those
involves the built-in conflicts of interests on the CIRM governing
board. As of September, 92 percent of the $1.7 billion handed out by the agency had gone to institutions linked to persons serving on the 29-member board.
The report said,

“Far too many board mem­bers
represent organizations that receive CIRM funding or benefit from
that funding. These com­peting personal and professional
interests com­promise the perceived independence of the ICOC(the
CIRM governing board), introduce potential bias into the board’s
decision making, and threaten to undermine confidence in the board.”

The IOM cited an ongoing scandal in Texas dealing with that state's $3 billion cancer agency. The flap
has led to mass resignations of the agency's grant reviewers. The
IOM said,

“Recent controversy surrounding the
Cancer Prevention and Research Institute of Texas grants process
illustrates the importance of rigorous scientific review free from
inherent or perceived conflict and the consequences when these
boundaries appear to be breached.”

However, the IOM press release said,

“Because the committee was not
charged with reviewing CIRM's past funding decisions, it did not
identify any specific cases of conflict.”

The IOM surveyed members of the board (ICOC) about conflicts of interest. The report said,

 "While a majority of respondents stated
that personal interests did not play a role in their work on
the ICOC, some responses were more equivocal. One respondent replied that it was 'hard
to tell' given that 'so many decisions take place off camera in secret meetings,' while another
acknowledged that ICOC members are human, and of course their decisions are influenced by
personal beliefs and interests."

To help deal with conflicts of
interest, the IOM recommended that the CIRM governing board not be
allowed to approve individual grants. Instead, the board would be
given a slate of applications that would be approved as a block. All
CIRM board members would be removed from the grant review committee
and the grant review process would be turned over to the president of
the agency, currently Alan Trounson.
The IOM recommended that a majority of
the board consist of “independent” members and said that the
board should not be increased beyond its current 29 members, although
it could be shrunk.
Conflict of interest rules should be
revised to deal with personal conflicts, which could have a major
impact on the 10 patient advocate members of the board but also
other directors and possibly staff who have family members with health issues. The report said,

“California law focuses primarily on
financial conflicts of interest, but the committee believes that
personal conflicts of interest arising from one’s own or a family
member’s affliction with a particular disease or advocacy on behalf
of a particular disease also can create bias for board members.
Studies in psychology and behavioral economics show that conflict of
interest leads to unconscious and unintentional 'self-serving bias'
and to a 'bias blind spot' that prevents recognition of one’s own
bias. Bias distorts evaluation of evidence and assessment of what is
fair.”

The IOM said that the board is much too
involved in operational matters, including the chair and the two
vice-chairs. The report said,

“The board should transfer management
responsibilities to management so it can provide truly independent
oversight and evaluation of management, strategic planning, and broad
direction for resource allocation.”

The IOM repeatedly and favorably cited
a 2009 study by California's Little Hoover Commission, the state's good
government agency. It noted that CIRM rejected most of the commission's recommendations. The IOM also cited recommendations by the agency's own “external review” panel in 2010 and suggestions
this year from the first performance audit of the agency, which cost
CIRM $234,944.
Many of the IOM's recommendations would
require either legislative approval or another ballot initiative.
However, changes in the Prop. 71, the ballot initiative that created CIRM, require a politically difficult super, supermajority
vote (70 percent) of the both houses of the legislature and the
signature of the governor. The requirement was written into the
10,000-word initiative and has been used by CIRM to block legislation
that it did not favor.
Here is brief rundown on some of the
other IOM recommendations:
  • Greater engagement with industry to
    commercialize stem cell research. Noting that industry has received
    only 6 percent of the agency grants, the report said business
    representation on CIRM working groups and other committees “should
    be enhanced to leverage industry’s expertise and resources in
    product development, manufacturing, and regulatory approval in
    support of the ultimate goal of bringing therapies to patients.”
  • Elimination of the current process in
    which applicants rejected by reviewers appeal publicly to the
    governing board. Noting that 32 percent of “extraordinary
    petitions” have been successful, the report said they “undermine
    the credibility and independent work” of grant reviewers. Instead
    appeals would heard only by staff behind closed doors.
  • Creation of a new scientific advisory
    board, appointed by the CIRM president with a majority from outside
    of California, instead of multiple advisory groups. The report said,“Such an external board would be
    invaluable in vetting ideas for new RFAs, suggesting RFAs that
    otherwise would not have been considered, and helping CIRM maintain
    an appropriate balance in its research portfolio. Input from this
    board would help CIRM make fundamental decisions about dealing with
    challenges that cut across particular diseases, decide which
    discoveries should progress toward the clinic, and determine how best
    to engage industry partners in developing new therapies.”
  • Funding of programs on bioethics and
    regulatory problems. The report said,“It is difficult for researchers to
    find appropriate funding for stem cell-specific ethics and policy
    work, and filling this funding gap is well within CIRM’s budget.”
One final note: As mentioned
earlier, Duane Roth, co-vice chairman of the agency, was the only no
vote on the board when it authorized the IOM study in 2010. The IOM today said,

“The critical tasks performed by the
vice chairs should be reassigned to management. In particular, the
important tasks of government relations and corporate relations both
should be carried out by staff reporting to the president rather than
by the vice chairs of the board.”

For more excerpts from the report, see this item.
,  

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/O67cWrCCsco/iom-recommends-sweeping-changes-at.html

To Read More: IOM Recommends Sweeping Changes at California Stem Cell Agency
categoriaStem Cell Therapy commentoComments Off on IOM Recommends Sweeping Changes at California Stem Cell Agency | dataDecember 9th, 2012
Read All

Text of CIRM Chairman’s Comments on the IOM Report

By Dr. Matthew Watson

Here is the text of comments on the IOM study of CIRM from J.T. Thomas, chairman of the agency. 

"We deeply appreciate all the hard work of the IOM committee in compiling  long and detailed report and the IOM clearly put considerable thought into compiling it. This has just been released so our Board and our staff has not had a chance to look at it yet, let alone digest its findings and recommendations, so it’s premature for us to offer any opinions. We are looking forward to the IOM presentation at the next meeting of our board, the Independent Citizens Oversight Committee (ICOC) where we’ll have a chance to talk with the IOM directly about the report. After that we’ll put together a process on how best to proceed so that we can respond in as thoughtful a manner to the recommendations as the IOM did in making them."

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/YkRTcgnXNqU/text-of-cirm-comments-on-iom-report.html

To Read More: Text of CIRM Chairman’s Comments on the IOM Report
categoriaStem Cell Therapy commentoComments Off on Text of CIRM Chairman’s Comments on the IOM Report | dataDecember 9th, 2012
Read All

Page 633«..1020..632633634635..640650..»


Copyright :: 2025